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Abstract Alteplase has been shown to be effective in
preventing central venous access clotting in patients on
hemodialysis. Because of a high phosphorus content in its
excipient, it can inadvertently contaminate blood samples,
leading the physician in care of the patient to erroneously
increase dialysis time or change diet in order to control
the pseudo-hyperphosphatemia.
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Vascular access remains a major problem in patients with
chronic kidney disease on hemodialysis, because of the
very high frequency of complications such as catheter-
related infections or thrombosis [1]. To prevent clotting
during the inter-dialysis period, highly concentrated
heparin has been routinely used, with diverse success
rates. Urokinase or recombinant tissular plasminogen
activator (rt-PA) have traditionally been used as throm-
bolytic agents for hemodialysis vascular access declotting
[2]. More recently, rt-PA has also been used instead of
heparin to prevent catheter occlusion, and several studies
have shown rt-PA to be superior to heparin in regard to
catheter flow and pressure performances and clot weight
[3, 4]. Because of the very high content of phosphorus in
Actilyse (Boehringer Ingelheim, Basel, Switzerland),
contamination of blood samples taken through the central
venous catheter is possible, if rt-PA has not been removed
sufficiently. We here report the occurrence of surrepti-
tious elevated phosphorus levels in a child because of the
high phosphate content of rt-PA contaminating the blood
sample.
A 3-year-old patient suffering from end-stage kidney
disease has been dialyzed 3.5 h, three times a week,
without any problems for several months. Because of poor
blood flow through his central venous catheter, we re-
cently used Actilyse instead of heparin to lock his catheter
during the inter-dialytic period, which markedly im-
proved his catheter blood flow. Shortly after, we noticed
very high and fluctuating phosphorus levels before dial-
ysis. The patient’s mother said she had not modified his
diet, and the dialysis nurse used the same routine, re-
moving and discarding the first 2–3 ml of blood in the
central venous catheter before taking blood for chemical
analysis. The child was not getting phosphate-containing
drugs [5]. Because the occurrence of sometimes extreme
hyperphosphatemia could not be explained by diet or poor
dialysis performance, we questioned the reliability of the
phosphorus analysis and considered possible contamina-
tion with Actilyse and the phosphoric acid used as an
excipient. Several simultaneous phosphorus measure-
ments by the central line and in periphery showed striking
differences in the phosphorus content, varying greatly
from sample to sample (Table 1). Each vial of Actilyse
contains 107.2 mg of phosphoric acid for 10 mg of Ac-
tilyse. When reconstituted with sterile water, this gives a
concentration of 109 mmol/l. An analysis of the recon-
stituted Actilyse (10 mg in 10 ml sterile water) showed a
phosphorus concentration of 111 mmol/l (the other anal-
ysis being the following: sodium <0.5 mmol/l, potassium
<0.1 mmol/l, chloride <10 mmol/l, calcium <0.1 mmol/l,
and total proteins <2 g/l).
Because of its properties, phosphorus is extensively
used in the pharmaceutical industry as buffering agent [6],
as is the case with Actilyse. In the case of improper
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rinsing of the catheter, contamination of the blood sample
is very likely to occur. This can have dramatic conse-
quences (change in diet, increasing the length of dialysis)
in patients with chronic kidney disease on dialysis. After
ruling out other causes of pseudo-hyperphosphatemia
such as sample contamination with heparinized saline [7]
or interference with paraproteins or hyperlipidemia [8, 9,
10], clinicians, and especially nephrologists, should be
aware of this possible contamination of blood samples
with phosphate due to improper rinsing when using
phosphate-containing rt-PA such as Actilyse. A volume of
blood equal to twice the dead volume of the indwelling
line should be discarded before drawing blood for non-
coagulation tests, in order to avoid interference with the
drug left in place.
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Table 1 Several simultaneous phosphorus measurements (in
mmol/l) by the central line and in periphery showed striking dif-
ferences in phosphorus content, varying greatly from sample to
sample
Sample Central line sample Peripheral blood sample
1 6.14 2.21
2 2.77 1.39
3 7.18 1.81
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